328 related articles for article (PubMed ID: 31292800)
1. Muscle composition and outcomes in patients with breast cancer: meta-analysis and systematic review.
Aleixo GFP; Williams GR; Nyrop KA; Muss HB; Shachar SS
Breast Cancer Res Treat; 2019 Oct; 177(3):569-579. PubMed ID: 31292800
[TBL] [Abstract][Full Text] [Related]
2. Myosteatosis and prognosis in cancer: Systematic review and meta-analysis.
Aleixo GFP; Shachar SS; Nyrop KA; Muss HB; Malpica L; Williams GR
Crit Rev Oncol Hematol; 2020 Jan; 145():102839. PubMed ID: 31877534
[TBL] [Abstract][Full Text] [Related]
3. Association of Muscle and Adiposity Measured by Computed Tomography With Survival in Patients With Nonmetastatic Breast Cancer.
Caan BJ; Cespedes Feliciano EM; Prado CM; Alexeeff S; Kroenke CH; Bradshaw P; Quesenberry CP; Weltzien EK; Castillo AL; Olobatuyi TA; Chen WY
JAMA Oncol; 2018 Jun; 4(6):798-804. PubMed ID: 29621380
[TBL] [Abstract][Full Text] [Related]
4. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM
J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831
[TBL] [Abstract][Full Text] [Related]
5. Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane-Based Chemotherapy.
Shachar SS; Deal AM; Weinberg M; Nyrop KA; Williams GR; Nishijima TF; Benbow JM; Muss HB
Clin Cancer Res; 2017 Feb; 23(3):658-665. PubMed ID: 27489287
[TBL] [Abstract][Full Text] [Related]
6. Myosteatosis at diagnosis is adversely associated with 2-year survival in women with estrogen receptor-negative metastatic breast cancer.
Sheean P; Gomez-Perez S; Joyce C; O'Connor P; Bojko M; Smith A; Vasilopoulos V; Rao R; Sclamberg J; Robinson P
Breast Cancer Res Treat; 2021 Nov; 190(1):121-132. PubMed ID: 34389926
[TBL] [Abstract][Full Text] [Related]
7. Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index.
Choi Y; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
PLoS One; 2015; 10(10):e0139749. PubMed ID: 26437072
[TBL] [Abstract][Full Text] [Related]
8. Assessment of body composition in the advanced stage of castration-resistant prostate cancer: special focus on sarcopenia.
Stangl-Kremser J; Suarez-Ibarrola R; Andrea D; Korn SM; Pones M; Kramer G; Marhold M; Krainer M; Enikeev DV; Glybochko PV; Tamandl D; Shariat SF; Baltzer P
Prostate Cancer Prostatic Dis; 2020 Jun; 23(2):309-315. PubMed ID: 31745255
[TBL] [Abstract][Full Text] [Related]
9. Sarcopenia reduces overall survival in unresectable oesophageal cancer: a systematic review and meta-analysis.
Jogiat UM; Bédard ELR; Sasewich H; Turner SR; Eurich DT; Filafilo H; Baracos V
J Cachexia Sarcopenia Muscle; 2022 Dec; 13(6):2630-2636. PubMed ID: 36151845
[TBL] [Abstract][Full Text] [Related]
10. Sarcopenia as a risk factor of severe laboratory adverse events in breast cancer patients receiving perioperative epirubicin plus cyclophosphamide therapy.
Ueno A; Yamaguchi K; Sudo M; Imai S
Support Care Cancer; 2020 Sep; 28(9):4249-4254. PubMed ID: 31900607
[TBL] [Abstract][Full Text] [Related]
11. Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy.
Rier HN; Jager A; Sleijfer S; van Rosmalen J; Kock MCJM; Levin MD
Breast; 2017 Feb; 31():9-15. PubMed ID: 27810702
[TBL] [Abstract][Full Text] [Related]
12. Sarcopenia and serum biomarkers of oxidative stress after a 6-month physical activity intervention in women with metastatic breast cancer: results from the ABLE feasibility trial.
Delrieu L; Martin A; Touillaud M; Pérol O; Morelle M; Febvey-Combes O; Freyssenet D; Friedenreich C; Dufresne A; Bachelot T; Heudel PE; Trédan O; Crochet H; Bouhamama A; Pilleul F; Pialoux V; Fervers B
Breast Cancer Res Treat; 2021 Aug; 188(3):601-613. PubMed ID: 34013451
[TBL] [Abstract][Full Text] [Related]
13. Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel.
Cushen SJ; Power DG; Murphy KP; McDermott R; Griffin BT; Lim M; Daly L; MacEneaney P; O' Sullivan K; Prado CM; Ryan AM
Clin Nutr ESPEN; 2016 Jun; 13():e39-e45. PubMed ID: 28531567
[TBL] [Abstract][Full Text] [Related]
14. Is sarcopenia a missed factor in the management of patients with metastatic breast cancer?
Deluche E; Lachatre D; Di Palma M; Simon H; Tissot V; Vansteene D; Meingan P; Mohebi A; Lenczner G; Pigneur F; Goldwasser F; Raynard B;
Breast; 2022 Feb; 61():84-90. PubMed ID: 34923226
[TBL] [Abstract][Full Text] [Related]
15. Low L3 skeletal muscle index associated with the clinicopathological characteristics and prognosis of ovarian cancer: a meta-analysis.
Jin Y; Ma X; Yang Z; Zhang N
J Cachexia Sarcopenia Muscle; 2023 Apr; 14(2):697-705. PubMed ID: 36720459
[TBL] [Abstract][Full Text] [Related]
16. Visceral Adiposity and Sarcopenic Visceral Obesity are Associated with Poor Prognosis After Resection of Pancreatic Cancer.
Okumura S; Kaido T; Hamaguchi Y; Kobayashi A; Shirai H; Yao S; Yagi S; Kamo N; Hatano E; Okajima H; Takaori K; Uemoto S
Ann Surg Oncol; 2017 Nov; 24(12):3732-3740. PubMed ID: 28871520
[TBL] [Abstract][Full Text] [Related]
17. The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma.
Rollins KE; Tewari N; Ackner A; Awwad A; Madhusudan S; Macdonald IA; Fearon KC; Lobo DN
Clin Nutr; 2016 Oct; 35(5):1103-9. PubMed ID: 26411749
[TBL] [Abstract][Full Text] [Related]
18. The association of body composition parameters and adverse events in women receiving chemotherapy for early breast cancer.
Aleixo GFP; Shachar SS; Deal AM; Nyrop KA; Muss HB; Chen YT; Yu H; Williams GR
Breast Cancer Res Treat; 2020 Aug; 182(3):631-642. PubMed ID: 32519169
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review.
Shachar SS; Williams GR; Muss HB; Nishijima TF
Eur J Cancer; 2016 Apr; 57():58-67. PubMed ID: 26882087
[TBL] [Abstract][Full Text] [Related]
20. Body composition measures as a determinant of Alpelisib related toxicity.
Shachar E; Raphael A; Katz U; Kessner R; Shachar SS
Breast Cancer Res Treat; 2024 Jul; 206(2):369-376. PubMed ID: 38584192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
